Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 0.71 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.71 |
| ▸ | PGR | P06401 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | AR | P10275 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.65 |
| ▸ | BLM | P54132 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topterone SCHEMBL3844149 | 1.00 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Topterone SCHEMBL8846971 | 1.00 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Topterone SCHEMBL11730925 | 1.00 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL11728942 | 0.93 | SHBG (0.68) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL10393805 | 0.93 | SHBG (0.68) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL8236612 | 0.93 | SHBG (0.68) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL6705535 | 0.92 | SHBG (0.67) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL6705536 | 0.92 | SHBG (0.67) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL29437217 | 0.91 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL3946610 | 0.91 | SHBG (0.74) | SHBGNR3C1PGRALDH1A1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177759-A1 | COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA-GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2018-06-28 | — | — | US | claimed |
| EP-3285753-A1 | COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA -GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER | CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) | 2018-02-28 | — | — | EP | claimed |
| WO-2016170102-A1 | COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA -GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2016-10-27 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120028910-A1 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS | FOVEA PHARMACEUTICALS (FR) | 2012-02-02 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | JENNINGS-SPRING BARBARA L | 2008-06-12 | — | — | US | claimed |
| WO-2008066634-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | JENNINGS-SPRING BARBARA L (US) | 2008-06-05 | — | — | WO | claimed |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2008-05-01 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SHBG 1564/4885NR3C1 413/4885PGR 2470/4885 |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | PGF, ERH, BRCA1 | SHBG 444/4885NR3C1 780/4885PGR 739/4885 |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | PPIP5K2, SHBG, CYP24A1 | SHBG 2/4885NR3C1 751/4885PGR 364/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SHBG 1564/4885NR3C1 413/4885PGR 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.